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Abstract
Background and Aim: Prior studies reporting that bariatric surgery (including laparoscopic adjustable gastric band
(LAGB) and [laparoscopic Roux-en-Y] Gastric Bypass (LRYGB)) is cost-saving relied on a comparison sample of
those with a morbid obesity (MO) diagnosis code, a high cost group who may not be reflective of those who opt for
the procedures. We re-estimate net costs and time to breakeven using an alternative sample that does not rely on
this code.
Materials and Methods: Non-randomized case-control study using medical claims data from a commercial database
in the USA. LAGB and LRYGB claimants were propensity score matched to two control samples: one restricted to
those with a MO diagnosis code and one without this restriction.
Results: When using the MO sample, costs for LAGB and LRYGB are recovered in 1.5 (Confidence Interval [CI]:
1.45 to 1.55) and 2.25 years (CI: 2.07 to 2.43), and 5 year savings are $78,980 (CI: 62,320 to 100,550) for LAGB and
$61,420 (CI: 44,710 to 82,870) for LRYGB. Without the MO requirement, time to breakeven for LAGB increases to
5.25 (CI: 4.25 to 10+) years with a 5 year net cost of $690 (CI: 6,800 to 8.400). For LRYGB, time to breakeven
exceeds 10 years and 5 year net costs are $18,940 (CI: 10,390 to 26,740).
Conclusions: The net costs and time to breakeven resulting from bariatric surgery are likely less favorable than has
been reported in prior studies, and especially for LRYGB, with a time to breakeven of more than twice the 5.25 year
estimate for LAGB.
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Severely obese individuals are at greater risk of diabetes and
other chronic conditions and have annual expenditures that far
exceed expenditures for those with a normal BMI [1,2].
Bariatric surgery, including gastric banding and gastric bypass
surgery, is the most effective treatment for severe obesity. Both
procedures, which are typically performed laparoscopically,
have been shown to generate significant weight loss,
improvements in comorbidities, most notably diabetes [3,4],
and have been shown to be cost-effective [5,6]. Although
average costs in the USA for the procedures are roughly
$20,000 for the laparoscopic adjustable gastric band (LAGB)
and $24,000 for the [Laparoscopic Roux-en-Y] Gastric Bypass
(LRYGB), it is possible that the reduction in comorbidities may
lead to a net cost savings [7,8].
Although no randomized studies have been conducted to
test this hypothesis, several case control studies have explored
the net cost implications [7,9-11]. Three of these studies found
that costs were recovered in 4 years or less. Contrarily,
Maciejewski et al [11], focusing on mostly older male patients
who received gastric bypass surgery at Veterans
Administration (VA) medical centers, found no evidence of
reduced health expenditures post surgery. A primary difference
with their study is that it is the only one that did not rely on the
use of an MO diagnosis code to identify controls. The MO code
is largely given to those with BMIs well above 40 who are likely
to present with medical conditions that can often lead to rapid
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escalation of costs. As such use of this code may not be
appropriate to identify an appropriate control group of bariatric
surgery patients.
The aim of this study is to generate net costs and time to
breakeven estimates for private sector LAGB and LRYGB
patients using a comparison sample not restricted to the MO
diagnosis code but propensity score matched to the surgery
samples on other observable demographic and comorbidity
variables. We hypothesize that results based on this sample




The analysis is based on claims data from the MarketScan®
Commercial Claims and Encounters database between
January 1, 2003, and September 31, 2009.
The database includes de-identified, person-specific
inpatient, outpatient, and retail pharmaceutical claims from
approximately 100 large payers representing millions of
covered lives. The claims include visit-level information,
including dates of service, diagnosis and procedure codes, and
payments. For the surgically treated patients it includes the
costs of surgical follow-up and complications. A linked patient-
level file provides additional demographic data, including age
and gender, type of health plan, and periods of eligibility [12].
The RTI International IRB deemed that the study, involving
secondary data analyses on bariatric surgery using
MarketScan® data, was exempt from review based on the
criteria that the research involved existing data where
information was recorded in a manner where subjects could not
be identified either directly or through identifiers linked to the
subjects.
Sample Selection
The matching strategy began with the LAGB sample. The
approach for selecting this sample has been discussed
previously [10]. In brief, all persons aged 18 to 64 with
evidence of a banding placement code (Healthcare Common
Procedure Code [HCPCS] S2082 and Current Procedural
Terminology [CPT] code 43770) and no evidence of stomach
or intestinal cancers (Internal Classification of Disease 9th
Edition [ICD-9] codes 150–159 and 230) were included.
Persons who did not have one of these two codes but had
evidence of either a banding adjustment or removal (HCPCS
code S2083; CPT codes 43771, 43772, 43773, and 43774; or
ICD codes 44.96, 44.97, or 44.98) were also included if an
initial LAGB procedure date could be identified using a wider
set of bariatric procedure codes commonly used before 2004. If
none of these codes were identified, or if there were multiple
bariatric procedure codes on different dates, then the individual
was not included in the analysis.
The LRYGB sample was identified using the following codes:
43644 and 43645 (CPT), S2085 (HCPCS), or 44.38 (ICD-9).
For both surgery samples, the date on which the initial
procedure occurred is indexed as the surgery date. The MO
comparison sample was identified using ICD-9 code V85.4 for
“BMI 40 and over, adult.” The random sample of 120,000
individuals was provided directly from Medstat. For all samples,
the subset with diabetes was defined as individuals with at
least two outpatient claims or one inpatient claim with a
diagnosis of diabetes (ICD 250).
Analysis
Propensity score matching was used to ensure that the four
groups were as similar as possible. LRYGB patients were
matched to LAGB patients based on patient and health plan
characteristics, and on diagnoses and costs in the year prior to
the quarter before the bariatric procedure. This 1-year window
was used to ensure that the claims occurring in the buildup to
the procedure did not influence the match. Operationally, the
LAGB and LRYGB samples were combined and a probit model
was used to predict the probability (propensity) of LAGB (as
opposed to LRYGB) as a function of observable
characteristics. The variables used in the match included age,
gender, type of health plan (Health Maintenance Organization
[HMO], Preferred Provider Organization [PPO], or
comprehensive), year of surgery, presence of obesity related or
highly prevalent comorbidities (including diabetes, asthma,
arthritis, hypertension, sleep apnea, dyslipidemia, migraines,
and chronic obstructive pulmonary disease), and inpatient and
total costs in each quarter of the match period.
Matching the MO and random samples to the LAGB sample
occurred similarly; however, before the match could occur, the
match period needed to be defined for the comparison samples
as they did not have a surgery date to reference. This was
resolved by assigning each individual in the control samples a
pseudo-surgery start date by randomly drawing from the
distribution of surgery dates for the LAGB sample. To further
improve the match and reduce the influence of outliers, cases
with an inpatient admission in the quarter prior to the (pseudo)
surgery date were removed out of concerns that comparison
sample cases who had an inpatient admission in this quarter
might be unlikely to have a bariatric procedure in the following
quarter. The most expensive 2.5% of cases from each sample
were also removed to minimize the influence of high cost and
potentially unrelated medical events on the results.
Nearest neighbor and one-to-one matching without
replacement was employed based on each individual’s
predicted value (propensity) for LAGB from the probit model.
This approach ensured that all samples matched the
comorbidity profile of the LAGB sample. An identical approach
was conducted for the diabetes subsample. However, it was
necessary to match to the LAGB sample with replacement to
create a suitable match.
Using the four matched samples, an analysis dataset was
created that included quarterly payments of total, inpatient
(both facility and physician), non-inpatient (including payments
for hospital outpatient, physician’s office visits, and emergency
department), and prescription drug claims. Each quarter
represented the time relative to (pseudo) band placement. All
payments were inflated to two thousand and eleven dollars
using the medical care component of the Consumer Price
Index. For each individual, data were dropped from all quarters
where a person was not fully enrolled. Differences in the
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(pseudo) surgery date and duration of enrollment resulted in
different observation lengths for each individual.
A maximum likelihood Tobit model was used to compare
quarterly payments for the LAGB, LRYGB, and control
samples. The Tobit model is appropriate because medical
expenditures are non-negative [13]. The model specification
included quarterly dummy variables and three dummy variables
representing LRYGB, MO, and random sample claimants, with
LAGB as the omitted reference group. To test for the costs of
LAGB relative to LRYGB or the controls in each quarter, the
model also included interactions between each quarterly
dummy variable and the LRYGB, MO, and matched random
sample indicators. Because the overall and diabetes samples
become small after quarters 16 and 12, respectively, data were
pooled beyond these quarters and a single indicator was used
to represent average quarterly costs for these quarters and
beyond.
The cost implications of LAGB can be quantified by using the
regression results to compare quarterly payment differences
between the LAGB, LRYGB, and comparison samples
beginning the quarter before (pseudo) surgery. The present
value of these payments in subsequent quarters, from the time
of initial placement, represents the net costs and was
calculated using an annual discount rate of 3%. Five-year net
costs and time to breakeven are presented based on 1,000
bootstrapped replications. All analyses were conducted using
Stata 11.1 [14].
Results
Table 1 presents summary statistics. 9,651 LAGB patients
met the inclusion criteria. These patients are predominantly
female and average 44 years old at the time of surgery.
Roughly 25% have diabetes, and the prevalence of
comorbidities ranged from 8.4% for asthma to 45% for arthritis.
Payments for the LAGB sample in the year before the quarter
before surgery averaged $9,971.
Relative to LAGB patients, LRYGB patients are slightly older
and have a different health plan mix and distribution across
years. They also have higher rates of diabetes (30.9% vs.
25.4%), asthma (9.7% vs. 8.4%), and sleep apnea (24.4% vs.
20.0%) and greater annual payments in the year prior to the
surgery quarter ($10,554 vs. $9,971).
The MO sample is roughly 3 years older than the LAGB
sample and has a smaller percentage of females (65.7% vs.
79.1%). The health plan mix and distribution across years also
Table 1. Panel A. Samples Prior to Matching and Trimming.
 Full Sample Diabetes Subsample
Population LAGB LRYGB Random Sample Morbid Obesity Sample LAGB LRYGB Random Sample
Morbid Obesity
Sample
Observations 9,651 21,533 120,175 10,907 2,455 6,646 6,850 2,461
Age (Years) 44.2 44.5* 44.0+ 47.1*+ 49 48.8 50.5*+ 52.2*+
Female (%) 79.1 79.4 68.3*+ 65.7*+ 71.2 72.3 62.5*+ 60.0*+
Health plan: PPO (%) 56.3 49.1* 52.6*+ 51.5*+ 57.8 51.7* 55.1*+ 53.5*
Health plan: HMO (%) 14.6 24.5* 28.4*+ 29.5*+ 14.1 22.4* 25.5*+ 25.9*+
Health plan: comprehensive (%) 6.6 7.5* 3.5*+ 4.3*+ 6.5 7.4 4.9*+ 5.8+
Diabetes (%) 25.4 30.9* 5.7*+ 22.6*+ 1 1 1 1
Asthma (%) 8.4 9.7* 2.7*+ 7.8+ 9.1 9.6 9 9
Arthritis (%) 44.8 45.6 22.7*+ 42.7*+ 49.3 49.8 50.2 52.9*+
Hypertension (%) 44.2 44.5 15.4*+ 28.8*+ 58.5 56.5 56.9 56.6
Sleep apnea (%) 20 24.4* 2.6*+ 11.5*+ 24.9 29.7* 16.4*+ 18.1*+
Migraines (%) 9.5 9.2 4.3*+ 1.4*+ 7.5 7 7.5 7.8
Dyslipidemia (%) 31.6 31 17.8*+ 7.9*+ 45.7 44.2 47.2+ 49.5*+
COPD (%) 4.9 5.9* 1.8*+ 5.8* 6.4 7.5 7.7* 8.7*
Inpatient payments (Q -2) 299.6 282.2 181.2*+ 1,321.9*+ 459.7 428.8 1,025.1*+ 2,009.9*+
Inpatient payments (Q -3) 353.8 345.8 268.3 773.0*+ 468.5 485.9 1,202.9*+ 1,273.2*+
Inpatient payments (Q -4) 342.1 375.3 236.0*+ 517.9*+ 459.9 529 1,137.4*+ 856.9*+
Inpatient payments (Q -5) 451.8 453.3 204.3*+ 573.6+ 704.1 597.3 1,003.9*+ 797.3
Total payments, 1 year before
procedure 9,971.30 10,554.3* 4,831.4*+ 11,497.1*+ 14,612.60 14,628.30 16,257.0*+ 17,887.5*+
* Different from the LAGB group at the 95% level.
+ Different from the LRYGB group at the 95% level.
Notes: COPD = chronic obstructive pulmonary disease; HMO = health maintenance organization; LAGB = laparoscopic adjustable gastric band; LRYGB = Laparoscopic
Roux-en-Y Gastric Bypass; PPO = preferred provider organization; Q = quarter
doi: 10.1371/journal.pone.0075498.t001
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differs. Moreover, although the prevalence of the included
comorbidities is statistically lower than in the surgery samples,
the annual costs are more than $1,500 greater for the MO
sample. This suggests that other differences are making this
sample more expensive.
The random sample differed markedly from all three
samples. This sample had a lower proportion of females and a
different health plan mix. It was also far healthier and had costs
that were less than half of the costs for the other samples.
Within each sample, the subset with diabetes tended to be
older, sicker, more expensive, and more likely to be male.
Relative differences across the four samples were similar.
Table 2 reveals that after propensity score matching, for the
full samples there were no statistically significant differences
between the LRYGB, random, and LAGB samples. Although
the propensity scoring approach was unable to increase the
comorbidity profile of the MO sample to fully match the surgery
samples, post matching there were no statistically significant
differences in costs in the reference period, suggesting the
match may still be appropriate. To the extent that the MO
sample may be slightly healthier, this would bias the estimates
toward a longer breakeven period for the surgeries. Among the
subset with diabetes, post matching there were no statistically
significant differences in costs or comorbidities across
samples.
Figures 1 and 2 provide graphical representations of the cost
trends pre- and post- (pseudo) surgery for total, inpatient,
outpatient, and pharmaceutical costs. The surgery quarter, Q1,
is not included on these graphs as including this quarter would
reduce the scale to the extent that trends would not be
observable. Costs for the LAGB and LRYGB samples in this
quarter were $21,980 and $29,900 for the full sample and
$22,480 and $31,150 for the diabetes subsample, respectively.
These figures reveal a slight increase in costs for the surgery
samples in the run-up to surgery.
Additionally, there is a reduction in costs from trend in the
quarter after surgery. The largest relative effects occur for
pharmaceutical payments, where costs decrease in quarter 2
for the full samples and diabetes subsamples and remain lower
than pre-surgery costs throughout the analysis period. This
decrease is largely driven by a reduction in costs for diabetes
medications (results available upon request).
There is no reduction from trend for the matched random
sample, whose costs increase in a linear fashion throughout
Table 2. Panel A. Samples After Matching and Trimming.
 Full Sample Diabetes Subsample
Population LAGB LRYGB Random Sample
Morbid Obesity
Sample LAGB LRYGB Random Sample
Morbid Obesity
Sample
Observations 9,631 9,631 9,631 9,639 2,447 2,447 2,447 2,455
Age (Years) 44.2 44.1 44.2 46.5*+ 49 48.9 48.9 48.4*
Female (%) 79.2 78.9 79.3 70.1*+ 71.3 71 72.8 70.9
Health plan: PPO (%) 56.4 55.6 55.9 54.6* 57.9 56.9 57.5 59.7
Health plan: HMO (%) 14.7 14.3 14.2 24.5*+ 14.1 13.5 13.9 12.8
Health plan: comprehensive (%) 6.6 7.6* 7 4.7*+ 6.5 7 6 7.3
Diabetes (%) 25.4 25.6 25.7 23.5*+ 1 1 1 1
Asthma (%) 8.5 8.6 8.7 7.8+ 9.1 9.8 9.6 8.9
Arthritis (%) 44.8 44.9 45.3 43.5 49.2 50.5 49.4 49.4
Hypertension (%) 44.2 44 44.6 38.9*+ 58.4 57.1 57.2 57.6
Sleep apnea (%) 20 20.4 20 12.6*+ 24.7 24.3 25.2 24.3
Migraines (%) 9.5 9.6 9.6 8.5*+ 7.4 7.2 7.6 8
Dyslipidemia (%) 31.6 31.1 31.4 30.0* 45.7 46.2 43.6 46.3
COPD (%) 4.9 4.9 5.4 5.7*+ 6.3 5.6 6.5 5.5
Inpatient payments (Q -2) 269.90 278.00 279.2 536.1*+ 422.10 516.30 529.3 522.3
Inpatient payments (Q -3) 349.50 375.70 404.2 569.8*+ 466.20 389.50 494.6 411.8
Inpatient payments (Q -4) 342.50 337.60 345.6 395 461.50 385.90 403.2 504
Inpatient payments (Q -5) 425.80 499.50 384.6+ 531.3 658.60 493.00 686 425.4
Total payments, 1 year before
procedure 9,765.80 10,101.80 9912.8 10167.1 13,909.30 14,107.70 14274.3 13706.2
* Different from the LAGB group at the 95% level.
+ Different from the LRYGB group at the 95% level.
Notes: Matching was conducted “without replacement,” meaning that each comparison sample patient was represented once in the analysis. COPD = chronic obstructive
pulmonary disease; HMO = health maintenance organization; LAGB = laparoscopic adjustable gastric band; LRYGB = Laparoscopic Roux-en-Y Gastric Bypass; PPO =
preferred provider organization; Q = quarter
doi: 10.1371/journal.pone.0075498.t002
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the analysis period. Costs for the MO sample immediately
escalate post pseudo surgery, largely driven by a sharp
increase in inpatient costs, thus revealing significant underlying
differences between this and the matched random sample.
This increase in MO costs is driven by higher rates of
admissions. Roughly one-third of the MO sample had an
admission post pseudo-surgery, whereas this figure is 10% for
the remaining samples (results available upon request).
Table 3 presents the time to breakeven and 5-year net costs.
When compared to the MO sample, costs for LAGB and
LRYGB appear to be fully recovered in 1.5 (Confidence Interval
[CI]: 1.45 to 1.55) and 2.25 years (CI: 2.07 to 2.43),
respectively. As a result, these procedures appear to generate
significant savings at 5 years: $78,980 (CI: $62,320 to
$100,550) for LAGB and $61,420 (CI: $44,710 to $82,870) for
LRYGB. Some of the difference in savings between the two
procedures results from the higher estimated surgical costs for
LRYGB ($16,680 vs. $22,140). Results appear even more
compelling for the diabetes subsample, with costs fully
recovered in 1.25 (CI: 1.02 to 1.48) years for LAGB and 1.75
(CI: 1.49 to 2.01) years for LRYGB and even larger estimated
savings at 5 years; $127,590 (CI: $94,840 to $167,590) for
LAGB and $103,340 (CI: $65,550 to $146,760) for LRYGB.
Figures 1 and 2 reveal that when comparisons are made to
the matched random sample, the estimated time to recover the
costs of a LAGB procedure increases to 5.25(CI: 4.25 to 10+)
years for the full sample. Five-year net costs (not savings) are
$690 (CI: $-8,400 to $6,800). For LRYGB net costs at 5 years
are $18,940 (CI: $10,390 to $26,740). Based on projections, it
would take more than 10 years to recover the costs of the
LRYGB procedure.
Focusing on the diabetes subsample, when comparing to the
matched random sample the estimated time to recover the
costs of a LAGB procedure is 4.25 (CI: 3 to 10+) years and
five-year net costs are now negative, revealing a savings of
$3,060 (CI: $-7,930 to $13,230). For LRYGB, the net costs
Figure 1.  Full Sample – Mean Medical Expenditures By Quarter.  Panel A illustrates Mean Total Payments after matching in the
Full Sample. Panel B illustrates Mean Inpatients Payments after matching in the Full Sample. Panel C illustrates Mean Outpatient
Payments after matching in the Full Sample. Panel D illustrates Mean Pharmaceutical Payments after matching in the Full Sample.
For scaling purposes, Q1 costs have not been included in the graph. The surgical date has been replaced with a red line. Comp is
short for comparison sample; MO is short for morbid obesity.
doi: 10.1371/journal.pone.0074935.g001
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remain positive (i.e., no savings) at 5 years; $21,610 (CI:
$3,330 to $42,570) and, based on projections, it would again
take more than 10 years to recover the costs of the procedure.
Discussion
The return on investment for bariatric surgery, be it banding
or bypass, depends on 3 factors: 1) the cost of the surgical
procedures, 2) the subsequent cost profile among those who
undergo the procedure, and 3) what their costs would have
been in the absence of the surgical intervention. Concerning
points 1 and 2 there is near universal agreement as this
information is readily available from claims data. The challenge
is predicting what costs would have been in the absence of
surgery. Without the benefit of a randomized trial, researchers
have had to construct convenience samples that they assume
mirror the experience of surgery patients had they not
undergone the procedure. Because BMI data is not typically
available in claims data, researchers have used those with an
MO code as a proxy for the surgery eligible population. This
group is indeed eligible for surgery, however, they may be a
very high cost/high risk subset of the surgery eligible population
such that their subsequent health care experience is not truly
reflective of what the surgery population would have
experienced in the absence of the procedure. This is likely to
be the case as those with an MO code are a small subset of
the BMI 40+ population who typically were assigned this code
as the result of an inpatient visit that had obesity related
complications.
The matched random sample, by matching on comorbidities,
may be more reflective of the health and cost trajectory of the
surgery sample in the absence of the procedure. As additional
evidence to this point, Table 4 compares the age and
prevalence of three primary risk factors for obesity from our
matched random sample to two surgery eligible samples, those
Figure 2.  Diabetes Subsample – Mean Medical Expenditures By Quarter.  Panel A illustrates Mean Total Payments after
matching in the Diabetes Sample. Panel B illustrates Mean Inpatients Payments after matching in the Diabetes Sample. Panel C
illustrates Mean Outpatient Payments after matching in the Diabetes Sample. Panel D illustrates Mean Pharmaceutical Payments
after matching in the Diabetes Sample. For scaling purposes, Q1 costs have not been included in the graph. The surgical date has
been replaced with a red line. Comp is short for comparison sample; MO is short for morbid obesity.
doi: 10.1371/journal.pone.0074935.g002
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with a BMI of 35 to less than 40 and 40+ from the nationally
representative Medical Expenditure Panel Survey. Although we
are unable to ascertain the exact BMI of our matched random
sample from the claims data, this table shows that the matched
random sample is slightly older and has a greater prevalence
rate of each of the three primary comorbidities than even the
BMI 40+ population. As such, this group almost surely has an
average BMI of at least 35 and because there is no MO code
indicating they are at especially high risk of deteriorating
health, may be a better representation of costs for surgery
eligible individuals in the absence of the procedure. As such,
the net benefits for bariatric procedures may be best seen by a
comparison to this sample.
Consistent with this hypothesis, use of the matched random
sample leads to more conservative estimates of the net costs
of the procedures. For LRYGB, the time to breakeven
increases from less than 2.25 years for the MO sample (1.75
years for the diabetes subsample) to well beyond 10 years for
the matched random sample for both the full and diabetes
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Note: LAGB = laparoscopic adjustable gastric band; LRYGB = Laparoscopic Roux-
en-Y Bypass
doi: 10.1371/journal.pone.0075498.t003
subsamples. Because of the small sample size and out of
sample forecasting required, an actual time to breakeven was
not reported. Regardless of the time to breakeven, it is worth
pointing out that the expectation for any surgical intervention to
show a return on investment is unusual and few effective
interventions reach this threshold. LAGB, however, may be one
of the exceptions.
For LAGB, net costs and time to breakeven were also less
favorable using the matched random sample. However, even
with this sample, the time to breakeven was just over 5 years
for the full sample and 4.25 years for the diabetes subsample.
Without a randomized trial we cannot definitively say which, if
any, of these results is closest to reality, however, these
findings, combined with the results of Maciejewski et al [11],
suggest that results based on the random sample are likely
more accurate.
This analysis is subject to several limitations. First, in
addition to how the comparison sample is constructed, the net
costs and time to breakeven were also influenced by the choice
of the matching variables, the determination of the pseudo
surgery date and matching period for the controls, the
elimination of extremely high cost cases, and whether the
match occurred with or without replacement. However, for each
strategy employed, restricting the match to those with an MO
code reduced the net costs and improved the time to
breakeven (results available upon request). Excluding the
highest 2.5% of cases from each group increased the expected
time to breakeven. Although the groups were matched on a
number of attributes, it was not possible to match on BMI
because this information was not available in the data.
However, because it is not limited to VA data, it is more
generalizable than the study by Maciejewski et al [11].
In conclusion, these results reveal that the net costs and time
to breakeven resulting from bariatric surgery are less favorable
than has been reported in prior studies. Yet, even with a more
conservative and likely more accurate comparison sample, the
business case for LAGB appears favorable. Regardless, the
decision of which procedure is right for a given individual
depends on many factors, although cost is likely to be a
significant consideration.
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&<40) MEPS data (BMI≥40)
Random Sample (After
Matching)
Observations 24,528 24,728 12,627 4,973 3,169 9,631
Age (Years) 37.4 41.4 42.6 42.7 42.5 44.2
Diabetes (%) 2.5 5.1 10.3 16.6 21.0 25.7
Hypertension (%) 8.6 17.4 27.5 34.3 42.9 44.6
Dyslipidemia (%) 7.3 14.8 19.8 21.0 20.2 31.4
doi: 10.1371/journal.pone.0075498.t004
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